A flexible population-based prescription opioid registry was established for addressing a broad range of critical public health questions relating to prescription opioid use.
G. Thomas Ray, MBA
Advertisement
Articles by G. Thomas Ray, MBA
A multigene test for breast cancer recurrence risk was used in a minority of eligible patients, yet was associated with a decrease in chemotherapy use.
Advertisement
Latest Updated Articles
- Breast Cancer Multigene Testing Trends and Impact on Chemotherapy Use
Published: May 17th 2016 | Updated:
- Prescription Opioid Registry Protocol in an Integrated Health System
Published: May 16th 2017 | Updated:
- Comparing the Medical Expenses of Children with Medicaid and Commercial Insurance in an HMO
Published: July 1st 2000 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
3
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
4
AMCP Nexus Bringing the Latest on Health Policy, Drug Access, and Value-Based Care
5
